MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/ph18030432

Медицинская библиотека · Pharmaceuticals (Basel, Switzerland) · 2025

Phenotyping the Use of Cangrelor in Percutaneous Coronary Interventions.

Pyrpyris Nikolaos, Dimitriadis Kyriakos, Kyriakoulis Konstantinos G, Soulaidopoulos Stergios, Tsioufis Panagiotis, Papanikolaou Aggelos, Baikoussis Nikolaos G, Antonopoulos Alexios, Aznaouridis Konstantinos, Tsioufis Konstantinos

СтатьяОбзорПеревод в очереди

Аннотация

The use of antiplatelet agents is essential in percutaneous coronary interventions, both periprocedurally and in the post-interventional period. Procedural antiplatelet therapy, aiming to limit ischemic complications, is mostly administered with oral agents, including aspirin and P2Y12 inhibitors. However, there are several limitations in the use of oral P2Y12 inhibitors, including their difficult administration in patients presenting with cardiogenic shock and their relatively slower onset of action, leaving a significant period of the procedure with a suboptimal antiplatelet effect. These pitfalls could be avoided with the use of cangrelor, the only available intravenous P2Y12 inhibitor, which has a rapid onset and offset antiplatelet effect, as well as a favorable pharmacological profile. The use of cangrelor has been increasing in recent years, with several studies aiming to determine what the optimal patient phenotype to receive such treatment ultimately is and how its use could be adjunctive to oral P2Y12 inhibitors. Therefore, the aim of this review is to provide an overview of the pharmacological profile of cangrelor and an update regarding the clinical evidence supporting its use, as well as to discuss the optimal patient phenotype, related clinical algorithms, and future implications for larger implementation of this agent into everyday clinical practice.

Для цитирования: Pyrpyris Nikolaos, Dimitriadis Kyriakos, Kyriakoulis Konstantinos G, Soulaidopoulos Stergios, Tsioufis Panagiotis, Papanikolaou Aggelos, Baikoussis Nikolaos G, Antonopoulos Alexios, Aznaouridis Konstantinos, Tsioufis Konstantinos. Phenotyping the Use of Cangrelor in Percutaneous Coronary Interventions.. Pharmaceuticals (Basel, Switzerland). 2025. DOI: 10.3390/ph18030432.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.